

AMENDMENT OF THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (previously presented) A soft gelatin capsule comprising Type A gelatin, said capsule containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form,

wherein the soft gelatin capsule comprising Type A gelatin exhibits a longer shelf life as compared to a soft gelatin capsule comprising Type B gelatin, and

wherein said soft gelatin capsule comprising Type B gelatin contains a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form.

2. (currently amended) The soft gelatin capsule as claimed in Claim 1 wherein formulation comprises 5, 8, 11, 14, 17-eicosapentaenoic acid (or "EPA") in free acid form.

3. (currently amended) The soft gelatin capsule as claimed in Claim 2 wherein EPA in free acid form is present in an amount of at least about 50 wt % of the formulation.

4. (currently amended) The soft gelatin capsule as claimed in Claim 2 wherein EPA in free acid form is present in an amount of between from about 50 wt % to about 60 wt % of the formulation.

5. (currently amended) The soft gelatin capsule as claimed in Claim 2 wherein EPA in free acid form is present in an amount of at least about 90 wt % of the formulation.

6. (currently amended) The soft gelatin capsule as claimed in Claim 1 wherein the formulation comprises 4, 7, 10, 13, 16, 19-docosahexaenoic acid (or "DHA") in free acid form.

7. (previously presented) The soft gelatin capsule as claimed in Claim 6 wherein DHA is present in an amount of between from about 20 wt % to about 30 wt % of the formulation.

8. (currently amended) The soft gelatin capsule as claimed in ~~any one of~~ Claim 1 comprising between from about 100mg to about 2000mg of said formulation.

9. (previously presented) The soft gelatin capsule as claimed in Claim 8 comprising about 500mg of said formulation.

10. (previously presented) The soft gelatin capsule as claimed in Claim 8 comprising about 1000mg of said formulation.

11-12. (cancelled)

13. (previously presented) The soft gelatin capsule as claimed in Claim 1 wherein the gelatin comprises porcine gelatin.

14. (previously presented) The soft gelatin capsule as claimed in Claim 1 wherein the gelatin comprises bovine gelatin.

15. (previously presented) The soft gelatin capsule as claimed in Claim 1 wherein the gelatin comprises fish gelatin.

16. (previously presented) The soft gelatin capsule as claimed in Claim 1 wherein the wall of the capsule consists of a single layer.

17. (previously presented) The soft gelatin capsule as claimed in Claim 1 wherein the capsule delays release of the formulation until after passage through the stomach.

18. (previously presented) The soft gelatin capsule as claimed in Claim 1 wherein the capsule delays release of the formulation until after passage beyond the pancreatic duct in the duodenum.

19. (previously presented) The soft gelatin capsule as claimed in Claim 17 wherein the capsule is coated with at least one enteric material.

20. (previously presented) The soft gelatin capsule as claimed in Claim 19 wherein at least one enteric material is integrated within the gelatin of the capsule.

21. (previously presented) The soft gelatin capsule as claimed in Claim 19 wherein the or at least one enteric material is a neutral polyacrylate polymer.

22. (previously presented) The soft gelatin capsule as claimed in Claim 20 wherein the or at least one enteric material is poly(ethylacrylate-methylmethacrylate).

23-34. (cancelled)

35. (currently amended) The soft gelatin capsule according to Claim 1, wherein the shelf life is determined by storing the soft gelatin capsule comprising Type A gelatin containing an omega-3 polyunsaturated fatty acid composition and the soft gelatin capsules comprising Type B gelatin containing an omega-3 polyunsaturated fatty acid for 3 months at a temperature of 40°C; disintegrating each of the capsules in water at 37°C; and calculating measuring disintegration times of each capsule to determine the shelf life of each capsule.

36. (currently amended) A soft gelatin capsule consisting essentially of Type A gelatin containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form, and

wherein the soft gelatin capsule exhibits a longer shelf life as compared to a soft gelatin capsule consisting essentially of Type B gelatin containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form, and

wherein the shelf life is determined by storing the soft gelatin capsule consisting essentially of Type A gelatin and the soft gelatin capsules consisting essentially of Type B gelatin for 3 months at a temperature of 40°C; disintegrating each of the capsules in water at 37°C; and ~~calculating~~ measuring disintegration times of each capsule to determine the shelf life of each capsule.

37. (previously presented) A soft gelatin capsule, comprising:
at least one omega-3 polyunsaturated fatty acid in free acid form; and
gelatin consisting essentially of Type A gelatin.

38. (new) The soft gelatin capsule according to claim 37, wherein the gelatin consists of Type A gelatin.

39. (new) A soft gelatin capsule comprising gelatin, wherein said soft gelatin capsule is filled with a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form, and

wherein the gelatin is such that the soft gelatin capsule has the property of disintegrating within 30 minutes in water at 37°C after being stored for 3 months at 40°C.

40. (new) The soft gelatin capsule according to claim 39, wherein the soft gelatin capsule consists essentially of Type A gelatin, and

wherein the soft gelatin capsule exhibits shorter disintegration time in water at 37°C after being stored for 3 months at 40°C as compared to a soft gelatin capsule

consisting essentially of Type B gelatin containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form.

41. (new) The soft gelatin capsule according to claim 39, wherein the soft gelatin capsule consists of Type A gelatin, and

wherein the soft gelatin capsule exhibits shorter disintegration time in water at 37°C after being stored for 3 months at 40°C as compared to a soft gelatin capsule consisting of Type B gelatin containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form.